Evidence map›Paper›PMID 28526907›Full record

Trial reportInternational journal of clinical oncology2017

A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).

Koji Ando, Yasunori Emi, Toyokuni Suenaga, Masahiro Hamanoue, Soichiro Maekawa, Yasuo Sakamoto, Seiichiro Kai, Hironaga Satake, Takayuki Shimose, Mototsugu Shimokawa and 7 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Koji AndoDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yasunori EmiDepartment of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Toyokuni SuenagaSurgery/Gastrointestinal Surgery, Public Interest Incorporated Association, Kagoshima, Nanpuh Hospital, Kagoshima, Japan.
Masahiro HamanoueDepartment of Surgery, Imakiire General Hospital, Kagoshima, Japan.
Soichiro MaekawaDepartment of Surgery, Munakata Medical Association Hospital, Fukuoka, Japan.
Yasuo SakamotoDepartment of Gastroenterological Surgery, Kumamoto University Hospital, Kumamoto, Japan.
Seiichiro KaiDepartment of Surgery, Nakatsu Municipal Hospital, Oita, Japan.
Hironaga SatakeDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Takayuki ShimoseClinical Research Support Center Kyushu, Fukuoka, Japan.
Mototsugu ShimokawaDepartment of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Hiroshi SaekiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. okieiji@surg2.med.kyushu-u.ac.jp.
Kenji SakaiDepartment of Medical Oncology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Yoshito AkagiDepartment of Surgery, School of Medicine, Kurume University, Fukuoka, Japan.
Hideo BabaDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yoshihiko MaeharaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kyushu Study Group of Clinical Cancer (KSCC)
Kyushu University · JPImakiire General Hospital · JPKobe City Medical Center General Hospital · JPKumamoto Medical Center · JPKumamoto University · JPKumamoto University Hospital · JPKurume University · JPKyushu Economic Research Center · JPNational Hospital Organization Kyushu Cancer Center · JPSaiseikai Fukuoka General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent colorectal cancer (CRC).

methodsThis was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated unresectable or recurrent CRC, presence of measurable lesions, ≥20 years of age, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients received bevacizumab (7.5 mg/kg on day 1) and XELIRI (irinotecan 200 mg/m

resultsA total of 36 patients were enrolled in this study from July 2011 to September 2012. One patient did not fulfill the eligibility criteria and one patient withdrew their consent before the start of the treatment protocol. The confirmed objective response rate was 58.8% (95% CI 35.1-70.2%). The median progression-free survival was 9.6 months (95% CI 5.1-11.1 months) and the median overall survival was 23.1 months (95% CI 11.3-36.7 months). The grade ≥3 adverse events that were frequently encountered in this study were neutropenia (31.4%), leukopenia (22.9%), diarrhea (22.9%), anemia (20.0%), anorexia (20.0%) and febrile neutropenia (17.2%). The frequency of grade 3/4 adverse events, such as neutropenia and leukopenia, was much higher in patients with a UGT1A1 polymorphism.

conclusionsA first-line therapy comprising XELIRI plus bevacizumab yielded a promising response rate. However, careful attention should be given to adverse clinical events in Japanese patients receiving treatment with unresectable or recurrent CRC.

Indexed as

AdultAgedAged, 80 and overAnorexiaAntineoplastic Combined Chemotherapy ProtocolsAsian PeopleBevacizumabCamptothecinCapecitabineColorectal NeoplasmsDiarrheaDisease-Free SurvivalFemaleFluorouracilGlucuronosyltransferaseHumansBevacizumabCamptothecinCapecitabineFluorouracilGlucuronosyltransferaseIrinotecanUGT1A1 EnzymeBevacizumabCapecitabineFirst-line chemotherapyIrinotecanMetastatic colorectal cancerMulticenter single-arm open-label prospective clinical trial

Identifiers

PMID28526907
OpenAlexW2616839175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.